Multiple Ophthalmic Devices and Diagnostic Systems Seeking Distributors or New Round of Financing – Special Ophthalmology Resource Matching Session

In recent years, China has focused on strengthening the construction of ophthalmic medical service systems, capacity building, and talent team development, continuously improving the ophthalmic medical quality control system, and promoting the expansion and extension of high-quality ophthalmic medical resources.This IssueBring to everyoneSeveralOphthalmic InstrumentsProducts andDiagnosis and Treatment System, seeking high-qualityDealer Cooperation;At the same time, multiple ophthalmology track enterprisesSeeking Financing, Details are as follows:

●Company/Product Introduction:

The First Commercial Adaptive Optics Fundus Imaging System - UgeneX®

Product Features:

AO-SLO System with a Resolution of up to 0.7μm

· Multiple advanced technologies achieve high-definition imaging: Adaptive optics technology, real-time eye-tracking technology

· Real-time navigation system + image stitching technology for large-scale imaging

· Retinal layer imaging technology can clearly present images of structures at different depths, such as capillaries, photoreceptor cells, and nerve fibers.

· A Variety of Quantitative Functions to Support Clinical Diagnosis and Treatment

· Various applications and research areas await further exploration.

● Demand Description:

Seeking distributors and partners across China. Interested parties are welcome to communicate.

● Company/Product Introduction:

Vistel is a national high-tech enterprise specializing in the application of artificial intelligence in the medical industry, particularly in the field of ophthalmology.

——Multi-disease Artificial Intelligence-assisted Diagnostic Software for Blinding Eye Diseases

The world's only ophthalmic multi-disease auxiliary diagnosis system that has obtained EU CE certification, passed the "Special Review Procedure for Innovative Medical Devices," completed registration clinical trials for more than 10 types of fundus diseases, and been officially approved for NMPA Class III medical device registration certificate.

AI analysis can be performed based on a single color fundus photograph of the posterior pole to determine the presence of abnormal lesions. It provides auxiliary diagnostic analysis for more than 10 types of fundus diseases, including glaucoma, epiretinal membrane, macular hole, and age-related macular degeneration, demonstrating excellent clinical results. It helps doctors accurately diagnose blinding diseases in fundus images, empowering early screening, diagnosis, and treatment of fundus diseases and glaucoma in China.

This product can be widely used in physical examination centers, grassroots medical institutions, and even ophthalmology institutions, significantly improving the current situation of the lack of grassroots ophthalmology professionals and insufficient disease diagnostic capabilities, promoting the realization of hierarchical diagnosis and treatment, while enhancing the efficiency of diagnosing and treating fundus diseases in large medical institutions.

● Requirement Description:

Seeking distributors and partners across China. Interested parties are welcome to communicate.

● Company/Product Introduction:

Simedice aims to build the world's largest high-end intraocular lens R&D, production, and manufacturing base by leveraging globally leading injection molding technology for intraocular lenses, combined with self-synthesized high-performance raw materials and advanced optical design from its proprietary patented inventions.

Simedice's MOM Technology Platform Introduces Stable, Clear, and Precise Intraocular Lenses through New Material Formulations, Accurate Optical Control, and Molding Technology. The products utilize acrylate material, which blocks ultraviolet and part of blue light, effectively protecting the surgical eye from light damage. The low glistenings performance and excellent biocompatibility of the material also enable patients to achieve better visual quality post-surgery. Rigorous optical design, precision manufacturing processes, and no traditional polishing—stricter than both domestic and international ISO standards—effectively reduce the probability of PCO and postoperative residual refractive errors.

Cooperation Business Advantages:
Good Product-Superior Performance During and After Surgery in Tens of Thousands of Cases Across 23 Countries Globally

Good Market-Focus on Investing in Professional Academic Market Construction

Good Price-Maximum discount, absolutely advantageous price

Good Management-Hospital Authorization System: Establish Effective Channel Management to Avoid Internal Friction and Inequity

● Demand Description:

1. Seek out mature ophthalmic distributors with medical device experience, possessing a certain level of financial strength, and who recognize the company's products and culture.

2、Going Global PlanMiddle Eastern countries. SeekingService Provider: ①Deep roots in the Middle East, with extensive knowledge of local policies, culture, and market.② Can help the product complete certification and approval.

● Company/Product Introduction:

TowardPi's "Intelligent Microscope System" as the first domestically developed high-end product in China, has the following significant advantages:
1. HD Visual Experience: The 3D-4K HD camera system provides surgeons with clear and comfortable visual feedback.
2. Precise 3D Visual Positioning: The built-in full-field swept-source OCT technology has a scanning speed of up to 400,000 times per second, enabling real-time 3D modeling and enhancing the precision and safety of surgeries.
3. Efficient Operation: The synchronous focusing function of the optical and digital systems enables more efficient transitions between anterior and posterior segment surgeries, overcoming the limitations of traditional optical microscopes.
4. Teaching Compatibility: The device supports teaching mode, suitable for internship training and surgical simulation for ophthalmologists, enhancing the learning experience.

● Requirement Description:

Looking forward to cooperating with high-quality distributors and medical institutions to jointly promote the development of ophthalmic surgical technology.

● Company/Product Introduction:

Jingze Biopharmaceuticals (Hefei) Co., Ltd. ("Jingze Bio") focuses on the fields of assisted reproduction and ophthalmology, committed to applying cutting-edge biotechnology for innovative research and development as well as industrialization, aiming to become a leading enterprise in these two fields in China.

In Jingze's product pipeline, one product has applied for NDA (Recombinant Human Follicle-Stimulating Hormone for Injection (rh-FSH), expected to receive production approval in October 2024); three products have entered Phase III clinical trials; and three products have entered Phase I clinical trials.

● Demand Description:

1. The C+ round of financing has completed the closing in March 2024 (RMB 380 million), officially entering the Pre-IPO stage, with a current valuation of RMB 2.9925 billion.
Financing Requirement for This Round: RMB 200 million - RMB 300 million, mainly used to advance the clinical trial progress of the products in the pipeline and the commercialization layout of related products.

2、Seeking cooperation on overseas rights and channels for the company's current R&D products and NDA-submitted products.

● Company/Product Introduction:

UgeneX is an ophthalmic disease drug company incubated by the Fosun Health Capital's New Drug Innovation Fund. The company focuses on the development of in vivo gene therapy products for ophthalmic diseases, targeting photoreceptor degenerative diseases and optic nerve degenerative diseases. Utilizing proprietary optogenetics and in situ transdifferentiation technologies, UgeneX independently develops optogenetic and optic nerve regeneration AAV gene therapy products.

Since its establishment three years ago, UgeneX has confirmed two technical routes: optogenetics and neuroregeneration, with three R&D pipelines in progress. The fastest pipeline has been advanced to IIT clinical trials, and some interim results have been published, showing excellent safety and efficacy.

● Demand Description:

The company is currently initiating a new round of financing and seeking interested partner institutions.

Chengdu Jinweike Biotechnology Co., Ltd. (referred to as Jinweike) is a company dedicated to the research and development of new AAV gene therapies for ophthalmic diseases, neuromuscular diseases, and genetic metabolic disorders.

As of now, Jinweike Biotechnology's product pipeline "JWK001," targeting neovascular age-related macular degeneration (nAMD), completed its first administration at West China Hospital in June this year. Patients reported good postoperative recovery with a significant improvement in best-corrected visual acuity (BCVA). The JWK001 pipeline submitted an Investigational New Drug (IND) application at the end of November this year, which has been accepted by the Center for Drug Evaluation (CDE) under the National Medical Products Administration.

In the field of rare disease treatment, Jinweike Biotechnology has laid out pipelines targeting indications such as hereditary ophthalmic diseases, inherited metabolic disorders, and neuromuscular diseases, all of which are currently in the preclinical research stage. Focusing on the star vector in gene therapy—recombinant adeno-associated virus (AAV)—Jinweike Biotechnology has built a complete technology chain for AAV gene therapy R&D based on four core proprietary technologies: "AAV gene expression cassette design technology, gene editing technology, large gene delivery technology, and AAV capsid modification technology."

● Demand Description:

Currently, Jinweike Biotechnology has initiated a new round of financing to advance the clinical progress of the company's research pipeline.. Seeking cooperation with investment institutions.

- VCBeat Supply and Demand Platform Coverage: Overseas Expansion, Supply Chain, Market/Channel, Achievement Transformation, Investment Attraction and Residency

- By uploading supply or demand resources through the platform, you can accurately reach potential target partners.

- Efficiently connect with MNCs, startups, government parks, investment institutions, and other entities.